Skip to main content
. 2022 Sep 1;14(17):4284. doi: 10.3390/cancers14174284

Figure 2.

Figure 2

Changes in the ALBI score at 3, 6, 12, 18, and 24 weeks from baseline in the periods of atezo/beva treatments. Deterioration of ALBI score was significant at 3 weeks (−2.41 vs. −2.22, p = 0.011); however, there was no deterioration in the ALBI score in the subsequent treatment. ALBI, albumin–bilirubin; atezo/beva, atezolizumab plus bevacizumab; n.s, not significant